Navigation Links
Baseline Research Indicates High Interest in Centocor-Ortho Biotech's SIMPONI(R)
Date:5/8/2009

EXTON, Pa., May 8 /PRNewswire/ -- BioTrends Research Group released highlights from its baseline wave of LaunchTrends(TM): SIMPONI, a four wave syndicated research study that will track uptake of the drug from FDA approval through six months post launch. The research is based on results of a survey of 77 Rheumatologists conducted on-line between May 5th and May 7th.

95% of the Rheumatologists surveyed were aware of SIMPONI and about one-third had been called on by SIMPONI sales representatives. Two-thirds reported a favorable reaction to SIMPONI and 83% reported a high interest in learning more about the product. Among those familiar with SIMPONI, nearly all were aware of the monthly dosing intervals, but overall the respondents were less familiar with the product's indications and dose delivery forms. Compared to the other biologics indicated for RA, 43% identified SIMPONI as the "easiest to administer/easiest for patients to take" while 26% gave Abbott's HUMIRA(R) top billing for ease of use. The respondents reported that close to 40% of their severe RA patients could be considered candidates for SIMPONI and that the majority of SIMPONI patients would be switched from other biologic agents. Market share projections suggest that SIMPONI will primarily draw from other TNF-inhibitors and 38% of the respondents suggest that they will prescribe the product for their RA patients as soon as it is available.

Surveyed Rheumatologists are also highly aware of other late stage biologics awaiting approval such as UCB's CIMZIA(R) and Roche's ACTEMRA(R). 62% of the respondents reported a greater interest in ACTEMRA compared to SIMPONI, primarily due to ACTEMRA's novel mechanism of action. Given a choice between SIMPONI and CIMZIA, the respondents reported a greater interest in SIMPONI by a 3:1 margin.

About SIMPONI

Centocor Ortho Biotech, Inc. received FDA approval for SIMPONI(R) (generic name: golimumab) on April 24, 2009. The first once-monthly subcutaneous anti-TNF-alpha therapy, SIMPONI is approved for the treatment of moderately to severely active rheumatoid arthritis, active psoriatic arthritis, and active ankylosing spondylitis. The product will be available in two dosing delivery forms: the SIMPONI SmartJect autoinjector and a prefilled syringe.

LaunchTrends: SIMPONI is a four wave primary market research study that consists of a quantitative on-line survey and qualitative telephone interviews. In total, 300 Rheumatologists will participate in the research. Following a baseline report, three additional waves will be published capturing launch effectiveness at one month, three months, and six months post launch. The reports are designed to assess trial and use of SIMPONI(R), obstacles to use, typical patient types, product perceptions, promotional efforts/messages, and satisfaction with the product relative to other agents. The full baseline report, which incorporates quantitative and qualitative results, will be published on May 22, 2009.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (http://www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or http://www.bio-trends.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.


'/>"/>
SOURCE BioTrends Research Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
4. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
5. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
6. eResearchTechnology to Present at the Thomas Weisel Healthcare Conference 2007 on September 5th
7. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
8. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
9. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
10. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
11. Richard Schulz Receives the Coveted GCPj Award for Best Clinical Researcher of the Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... Cell therapies for a range ... by research at Worcester Polytechnic Institute (WPI) that yielded a newly patented method ... , The novel method, developed by WPI faculty members Raymond Page, PhD, professor ...
(Date:5/23/2016)... ... ... blood donations in South Texas and across the nation is growing. , But according to ... are on the decline. In fact, donations across the country are at their lowest point ... the last four years alone. , There is no substitute for blood. , “We want ...
(Date:5/23/2016)... and LONDON , May 23, 2016 /PRNewswire/ ... See Frontage Boost Efficiency by 40% - Frontage Implement ... - Frontage Enforce Quality, Compliance and Traceability Within the Bioanalytical lab ... labs in the United States and ... to be deployed across its laboratory facilities. In addition to serving ...
(Date:5/20/2016)... ... May 20, 2016 , ... The leading Regenerative Veterinary Medicine Company, VetStem ... have treated over 100 of their own patients with the VetStem Cell Therapy. Each ... of care for their patients. , The veterinarians are Dr Ross Rich former ...
Breaking Biology Technology:
(Date:4/14/2016)... AVIV, Israel , April 14, 2016 ... Behavioral Authentication and Malware Detection, today announced the appointment ... already assumed the new role. Goldwerger,s leadership ... BioCatch, on the heels of the deployment of its ... addition, BioCatch,s behavioral biometric technology, which discerns unique cognitive ...
(Date:3/31/2016)... 2016   LegacyXChange, ... "Company") LegacyXChange is excited to release its ... to be launched online site for trading 100% guaranteed ... will also provide potential shareholders a sense of the ... an industry that is notorious for fraud. The video ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
Breaking Biology News(10 mins):